Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
809 articles by Ben Fidler
-
Arthrosi snags $153M in pursuit of a new gout drug
Oct. 8, 2025 -
Lexeo says FDA open to speedier approval of rare disease gene therapy
Oct. 7, 2025 -
Skye shares crash as obesity drug falls short in key study
Oct. 6, 2025 -
The top biopharma conferences in 2026
Oct. 1, 2025 -
Moonlake shares crash on mixed study results for immune drug
Sept. 29, 2025 -
Lilly’s oral SERD gets FDA nod in advanced breast cancer
Sept. 25, 2025 -
Scholar Rock SMA drug rejected by FDA over manufacturing concerns
Sept. 23, 2025 -
FDA clears under-the-skin Keytruda; MBX shares double on study data
Sept. 23, 2025 -
FDA clears first Barth syndrome drug amid scrutiny of rare disease stance
Sept. 22, 2025 -
Roche dives into MASH with $2.4B deal for 89bio
Sept. 18, 2025 -
Novartis dives deeper into protein degraders with second Monte Rosa deal
Sept. 15, 2025 -
Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership
Sept. 10, 2025 -
Bravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug
Sept. 5, 2025 -
Wave shares sink on new study results for RNA editing drug
Sept. 3, 2025 -
Drugs from China are reshaping biotech. Track the licensing deals here.
Aug. 25, 2025 -
Xoma, a drug royalty specialist, buys another ‘zombie’ biotech
Aug. 20, 2025 -
Novo’s Wegovy becomes first GLP-1 drug approved for MASH
Aug. 18, 2025 -
Vedanta, PureTech’s microbiome startup, to cut staff after study setback
Aug. 14, 2025 -
Expedition, a startup searching for drugs from China, cuts its first deal
Aug. 12, 2025 -
Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease
Aug. 11, 2025 -
Vinay Prasad, in surprise reversal, to rejoin FDA after abrupt departure
Aug. 9, 2025 -
FDA to start new ‘precheck’ program to boost US drug production
Aug. 7, 2025 -
Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy
Aug. 7, 2025 -
US biotech needs government support to match China’s gains, Pfizer CEO says
Aug. 5, 2025 -
David Altshuler, geneticist who helped transform Vertex, to retire next year
Aug. 5, 2025